Galimedix is a startup based in the United States.
Galimedix develops small molecule therapies targeting neurodegenerative diseases affecting the eye and brain, including dry age-related macular degeneration, glaucoma, and Alzheimer's disease, with its lead candidate GAL-101 currently in Phase 2 clinical trials.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.